Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress (NAPS)

30 avril 2018 mis à jour par: University of Chicago

Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome

This will be the first study of the effect of essential fatty acid supplementation in pregnant women living in inner-city poverty on the stress response system during pregnancy. The investigators proposed that essential fatty acid supplementation will be associated with reductions in the experience of stress, more modulated hormonal response to stress, and more optimal regulation of emotion and attention in the infant, even within the context inner-city poverty.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Significance: Pregnant women living in poverty often experience chronic stress, and consequently higher levels of stress hormones. In utero exposure to high levels of stress hormones can negatively affect the developing fetus and later, the infant's capacity for emotion and behavioral regulation. In this proposal we describe a developing program of research designed to reduce the negative impact of prenatal stress on infant health and development via nutritional supplementation of docosahexaenoic acid (DHA) during pregnancy. DHA is a long-chain polyunsaturated fatty acid member of the omega-3 fatty acid family. DHA is found in its highest concentrations in neural cell membranes, affecting receptor function, neurotransmitter uptake, and signal transmission. There is growing evidence that low levels of dietary DHA intake are associated with suboptimal response to stress and that DHA supplementation can modulate stress response. Aims: The goals of the proposed study are to explore whether DHA supplementation during pregnancy is associated with 1) a reduction in maternal perceived stress during pregnancy; 2) a more modulated maternal cortisol response to a stress stimulus during pregnancy, and 3) more optimal regulation of emotion and behavior in the infant. Approach: Sixty-five pregnant women living in inner-city poverty, who consume less than two servings of fish per week, will be randomly assigned to receive 450 mg/daily of DHA or placebo beginning at 16-20 weeks gestation through the end of pregnancy. Perceived stress, pregnancy related stress, stressful life events, anxiety, and depression will be assessed at baseline and at 24, 30, and 36 weeks of pregnancy and at 4 months post-partum. DHA levels will be assessed at baseline and at 36 weeks of pregnancy. Cortisol response to the Trier Social Stress Test will be measured at baseline, 24, and 30 weeks. At 4 months post-partum infant temperament, cognitive development and stress reactivity will be assessed in the laboratory. Investigators: This proposal stems from an National Institute of Mental Health R21 Translational Science Network on prenatal stress and mental health outcomes in the offspring. Three members of that network, Drs. Keenan, Carter, and Glover, are all funded investigators in the area of prenatal stress and child mental health, which is a prioritized area of exploratory research that could directly impact clinical care. They are collaborating on the present application. Innovation: This will be the first randomized controlled study of the effect of DHA supplementation on stress response in pregnant women living in inner-city poverty, and the first study of maternal DHA supplementation on emotion and stress regulation in their infants. Relevance: If DHA supplementation is associated with reductions in perceived stress, more modulated maternal cortisol response to stress, and more optimal emotional and behavioral regulation in the infant, even within the context inner-city poverty, then a comprehensive program of research on the mechanisms by which these associations evolve and the potential for broad-based prevention of poor developmental outcomes among children born to women living in poverty can be launched.

Type d'étude

Interventionnel

Inscription (Réel)

64

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • University of Chicago
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • University of Pittsburgh Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

20 ans à 34 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • African American race
  • age between 20 and 34 years
  • 16-21 weeks gestation
  • household receipt of public assistance (e.g., Medicaid insurance) due to -low-income
  • low levels of DHA consumption as defined as less than two fish servings per week.

Exclusion Criteria:

  • known medical complications (e.g., gestational diabetes, pre-eclampsia), -regular use of steroid medications
  • alcohol use
  • cigarettes or use of illegal substances (by maternal report)
  • use of blood thinners or anti-coagulants
  • use of psychotropic medications
  • Body Mass Index >40
  • allergy to iodine and/or soy.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: DHA supplementation
Complément alimentaire: Docosahexanoic Acid
450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
Autres noms:
  • Nordic Naturals ProDHA
Comparateur placebo: Soybean Oil
Autre: Placebo
soybean oils with strawberry flavoring

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Maternal Cortisol Levels
Délai: Baseline (pre-stressor)
Maternal stress regulation at 30 weeks gestation
Baseline (pre-stressor)
Maternal Cortisol Levels
Délai: 20 minutes post-stressor
Maternal stress regulation at 30 weeks gestation
20 minutes post-stressor
Maternal Cortisol Levels
Délai: 45 minutes post stressor
Maternal stress regulation at 30 weeks gestation
45 minutes post stressor
Infant Cortisol Levels
Délai: 4 months post-partum
Infant cortisol response to the Still-Face paradigm before stressor
4 months post-partum
Infant Cortisol Levels
Délai: 4 months post-partum
Infant cortisol response to the Still-Face paradigm 20 minutes post-stressor
4 months post-partum
Infant Cortisol Levels
Délai: 4 months post-partum
Infant cortisol response to the Still-Face paradigm 45 mins post-stressor
4 months post-partum

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Maternal Depression Symptoms
Délai: 16-21 weeks gestation

Maternal depression symptoms at 16 to 24 weeks gestation, as measured by the Edinburgh Postnatal Depression Scale, a 10-item measure designed to assess pre- and postnatal depression.

Maximum score: 30 Minimum score: 0 Possible Depression: 10 or greater Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity.
16-21 weeks gestation
Maternal Depression Symptoms
Délai: 24 weeks

Maternal depression symptoms at 24 weeks gestation as measured by the Edinburgh Postnatal Depression Scale, a 10-item measure designed to assess pre- and postnatal depression.

Maximum score: 30 Minimum score: 0 Possible Depression: 10 or greater Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity.
24 weeks
Maternal Depression Symptoms
Délai: 30 weeks gestation

Maternal depression symptoms at 30 weeks gestation, as measured by the Edinburgh Postnatal Depression Scale, a 10-item measure designed to assess pre- and postnatal depression.

Maximum score: 30 Minimum score: 0 Possible Depression: 10 or greater Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity.
30 weeks gestation
Maternal Perceived Stress Scale (PSS) Score
Délai: Baseline: 16 - 21 weeks

Perceived stress as measured by the Perceived Stress Scale (Cohen et al, 1983) at baseline. There are 10 questions in this scale and they all refer to typical life stressors.

Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.

  • Scores ranging from 0-13 would be considered low stress.
  • Scores ranging from 14-26 would be considered moderate stress.
  • Scores ranging from 27-40 would be considered high perceived stress
Baseline: 16 - 21 weeks
Maternal Perceived Stress Scale Score
Délai: 24 weeks gestation

Perceived stress as measured by the Perceived Stress Scale (Cohen et al, 1983) at 24 weeks gestation.

There are 10 questions in this scale and they all refer to typical life stressors.

Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.

  • Scores ranging from 0-13 would be considered low stress.
  • Scores ranging from 14-26 would be considered moderate stress.
  • Scores ranging from 27-40 would be considered high perceived stress
24 weeks gestation
Maternal Perceived Stress Scale Score
Délai: 30 weeks gestation

Perceived stress as measured by the Perceived Stress Scale (Cohen et al, 1983) at 30 weeks gestation.

There are 10 questions in this scale and they all refer to typical life stressors.

Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.

  • Scores ranging from 0-13 would be considered low stress.
  • Scores ranging from 14-26 would be considered moderate stress.
  • Scores ranging from 27-40 would be considered high perceived stress
30 weeks gestation
Infant Birth Weight
Délai: Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Weight of infant
Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Percentage of Infants Who Had a 1-minute Apgar Scores of 9
Délai: Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Percentage of infants who had a 1-minute Apgar scores of 9 Sub scores from 5 categories( Breathing effort, Heart rate, Muscle tone, Reflexes, Skin color) are added together Score range: 1-10 A higher score is better where 7,8,9 are normal
Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Gestational Age (GA)
Délai: Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Gestational Age at time of birth Total sample range: 27.60 to 41.60 weeks Below 37 considered premature Mothers typically induced after 41 weeks due to increased pregnancy risks after this time
Time of birth, total sample range: 27.60 to 41.60 weeks gestation
Infant's Receptive Communication Scaled Score
Délai: 3 months old

Scaled Score on Receptive Communication subscale of Bayley Scale for Infant Development that determines how well a child recognizes sounds and how much a child understands spoken words and directions compared to a group of children within the same age range from across the United States. Subscale consists of 49 items. Child'e scaled score is calculated from total raw scores.

Scaled score range: 1 - 12 Lower scores indicate more developmental delay.
3 months old
Infant's Expressive Communication Scaled Score
Délai: At approximately 3 months of age

Scaled Score for Expressive Communication subscale of Bayley Scale for Infant Development that determines how well a child recognizes sounds and how much a child communicates using sounds, gestures, or words compared to a group of children within the same age range from across the United States. Subscale consists of 48 items. Child'e scaled score is calculated from total raw scores.

Scaled score range: 2 - 9 Lower scores indicate more developmental delay.
At approximately 3 months of age
Infant's Fine Motor Skills Scaled Score
Délai: Approximately 3 months of age

Fine motor skills subscale score from Bayley Scale for Infant Development. Determines how well a child recognizes sounds and how much a child can use his or her hands and fingers to do things compared to a group of children within the same age range from across the United States. Subscale consists of 66 items. Child's scaled score is calculated from total raw scores.

Scaled score range: 1 - 8 Lower scores indicate more developmental delay.
Approximately 3 months of age
Infant's Gross Motor Skills Scaled Score
Délai: Approximately 3 months of age

Infants Gross Motor skills subscale score from Bayley Scale for Infant Development. Determines how well a child well your child can move his or her body compared to a group of children within the same age range from across the United States. Subscale consists of 72 items. Child's scaled score is calculated from total raw scores.

Scaled score range: 1 - 6 'Lower scores indicate more developmental delay.
Approximately 3 months of age

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Chicago

Collaborateurs

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 décembre 2009

Achèvement primaire (Réel)

1 juin 2013

Achèvement de l'étude (Réel)

1 juin 2013

Dates d'inscription aux études

Première soumission

28 juin 2010

Première soumission répondant aux critères de contrôle qualité

7 juillet 2010

Première publication (Estimation)

8 juillet 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 mai 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 avril 2018

Dernière vérification

1 avril 2018

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 09-190A
  • R21HD058269 (Subvention/contrat des NIH des États-Unis)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Femmes enceintes en bonne santé

Essais cliniques sur Docosahexanoic Acid

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Myanmar

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner